Goal
Inflammation
Measure something before and after, and be careful what you suppress.
Inflammation as a goal usually means one of two quite different things. Either there is a specific inflamed site or condition, which is measurable and often treatable, or there is a general sense of systemic inflammatory load, which is vague and usually better addressed by sleep, training load, alcohol and body fat than by anything injected. Working out which one you mean changes the entire list below.
KPV leads at 5 as the anti-inflammatory tail of alpha-MSH acting on NF-kB signaling, on animal and cell-culture evidence only. At 4 sit ARA-290, which has genuine randomized placebo-controlled phase 2 trials behind it in neuropathy, along with BPC-157 and LL-37. GHK-Cu, larazotide, TB-500 and thymosin alpha-1 follow at 3. Semaglutide appears at 2, which looks odd until you remember that weight loss itself lowers inflammatory markers — a useful reminder that on this page a compound can help by an entirely indirect route.
Measure something. C-reactive protein is cheap and it turns this from a feeling into a number you can act on. Then be careful about what you are suppressing: post-training inflammation is part of the adaptation signal, and blunting it around every session is not obviously a win. As with immune support, autoimmune disease moves this conversation to a clinician rather than a protocol.
How to read this
Match — how squarely it aims here
The weight the dataset gives this compound for this goal, 1 to 5. It describes intent and mechanism, not benefit, and not direction: a 5 means the compound acts hard on the system in question.
5/5Match strength 5 of 5primary useEvidence — whether anyone has shown it
Read from the compound’s evidence note and handling grade, for the compound as a whole rather than for this goal alone. A 5/5 match on animal data is a hypothesis, not a result.
- Human trialsRandomized or controlled human trials exist, or the compound holds a regulatory approval somewhere. Trials existing is not the same as trials succeeding — some of these were negative.
- Some human dataPublished human work exists but is small, early-phase, acute, or from a single group that nobody has replicated.
- Animal data onlyThe case rests on rodent and cell work. Doses shown are extrapolated, not established in people.
- Anecdotal onlyNo published trial record of any kind. Every number comes from vendor packaging and community practice.
11 compounds, strongest match first
Ranked for inflammation
Match 5/5 · Primary use
1
Match 4/5 · Strong secondary
3
Match 3/5 · Meaningful contributor
4
- 05GHK-CuSubQTopical1 mg–2 mg · typ 1.5 mgIntermediate3/5Match strength 3 of 5Some human data
- 06LarazotideOral500 mcg–2 mg · typ 500 mcgIntermediate3/5Match strength 3 of 5Human trials
- 07TB-500SubQIM200 mcg–500 mcg · typ 300 mcgIntermediate3/5Match strength 3 of 5Animal data only
- 08Thymosin Alpha-1SubQ800 mcg–3.2 mg · typ 1.6 mgIntermediate3/5Match strength 3 of 5Human trials
Match 2/5 · Marginal
3
Named stacks
Protocols built around this goal
Not sure this is your goal
Most people arrive wanting two or three of these at once, and the honest answer is usually to pick one and run it properly. The quiz weighs your goals against your experience, the routes you will tolerate and your contraindications, then shows its reasoning rather than just a name.
Take the quizOther goals
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.